News | November 24, 2014

Research Says Lung Cancer With Minimally-Invasive Adenocarcinoma Has 97.7 Survival Rate

lung cancer, adenocarcinoma

Lung cancer patients with minimally invasive adenocarcinoma have similar, positive five-year disease-free survival and overall survival rates as patients with adenocarcinoma in-situ.

November 24, 2014 – Lung cancer patients with minimally invasive adenocarcinoma (MIA) have similar, positive five-year disease-free survival (DFS) and overall survival (OS) rates as patients with adenocarcinoma in-situ (AIS), according to research presented at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology
 
Lung adenocarcinoma accounts for 60% of all non-small cell lung cancers and is the most common form of lung cancer in both smokers and non-smokers and patients younger than 45 years old. Bronchioloalveolar carcinoma is a type of adenocarcinoma that affects the cells lining the alveoli (small air sacs) of the lungs. Invasion occurs when the tumor extends beyond the alveolar lining and evokes a fibroblastic stromal response. These types of tumors, if =3 cm in size, are reclassified as AIS (no tumor invasion) or MIA (=0.5 cm of tumor invasion), according to the 2011 IASLC/American Thoracic Society /European Respiratory Society (IASLC/ATS/ERS) International Multidisciplinary Classification of Lung Adenocarcinoma. This study examines the difference in DFS and OS rates for patients with diseases classified as AIS and MIA and determines if it is beneficial to categorize tumors according to additional sub-types.
 
The study authors conducted a comprehensive search of studies published from 2011 to 2014 in the MEDLINE, Embase and Cochrane databases. Studies selected for analysis provided survival outcome data for at least eight cases classified as AIS or MIA based on the 2011 IASLC/ATS/ERS classification. Excluded studies did not report survival information. A systematic analysis of DFS and OS data was performed using the random effect model of the Comprehensive Meta Analysis (Version 2.2) software.
 
The study’s analysis included information from 18 clinical studies published from 2011 and 2014. The 18 studies included a total of 863 patients, with 451 patients classified as AIS and 344 patients classified as MIA. One study reported survival data on patients (68) with AIS and MIA grouped together. The median age of all patients was 67.5 years old. 61% of patients were female, and 43% of all patients were smokers. The median tumor size was 1.3 cm.  
 
The five-year DFS and OS rates were not statistically different between patients with AIS and MIA. The five-year DFS rate was 97.7% for all patients included in the analysis. The five-year DFS rate was 97% in patients with AIS and 96.7% in patients with MIA (p=0.34). The five-year OS rate was 97.3% for all patients included in the analysis. The five-year OS rate was 97.5% in patients with AIS and 96% in patients with MIA (p=0.58).
 
“Some researchers have advocated that AIS and MIA should have separate categorization,” said lead author Madhusmita Behera, Ph.D., associate director of research in the Department of Hematology and Medical Oncology at Winship Cancer Institute of Emory University in Atlanta. “Our analysis demonstrates that these carcinomas, especially when the tumor is 3 cm or less in size, are associated with excellent survival outcomes; therefore, tumor sub-classification into AIS and MIA may not provide additional prognostic information.”
 
For more information: thoracicsymposium.org/

Related Content

Lunit Unveiling AI-Based Mammography Solution at RSNA 2018
News | Mammography | November 15, 2018
Medical artificial intelligence (AI) software company Lunit will be returning to the 104th Radiological Society of...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...
The patient’s wife changes the Optune array. Clinical trials indicate that the electrical fields emitted by Optune have the potential to lengthen the lives of patients with glioblastoma.

The patient’s wife changes the Optune array. Clinical trials indicate that the electrical fields emitted by Optune have the potential to lengthen the lives of patients with glioblastoma.

Feature | Radiation Oncology | November 06, 2018 | By Greg Freiherr
Approximately 11,000 professionals attended the four-day meeting of the...
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation